supported by the Cultivation of Scientific Research Project of Changhai Hospital,Shanghai,China(No.2021JCMS20);Major Topics of the Health Commission of Jiangsu Province(ZD2021020).
The prevalence of mitral regurgitation(MR)is increasingly worldwide as a consequence of improved survival and ischemic heart disease.Severe MR is associated with worse prognosis,independent of left ventricular functio...
supported by the National Key R&D Program of China(2022YFC2503400);the Major Science and Technology Special Plan Project of Yunnan Province(202302AA310045).
The surgical treatment of isolated tricuspid regurgitation presents a notable mortality risk,particularly in patients who are referred late.Tricuspid transcatheter edge-to-edge repair(TEER)has become a safe and effect...
supported by funding from the second batch(for research and translation pre-evaluation of innovative medical biomaterials)and the third batch(for research on performance and safety evaluation of innovative biomaterial medical devices)of the Chinese Drug Regulatory Science Action Plan of the National Medical Products Administration.
For patients with symptomatic and severe tricuspid regurgitation but inoperable with open surgery,transcatheter tricuspid valve intervention(TTVI)is a procedure of great clinical value.TTVI products include repair and...
granted by Healthy Zhejiang One Million People Cohort(No.K-20230085).
To the Editor:Transcatheter aortic valve replacement(TAVR)has witnessed a rapid global surge and emerged as a viable alternative for treating aortic stenosis patients.Obesity,a well-established risk factor for the dev...
supported by grants from the National Natural Science Foundation of China(No.82172859,82071916,U20A20378,and 82188102);the Joint Fund for Regional Innovation and Development of National Natural Science Foundation of China(No.U23A20462).
Evidences regarding the feasibility of transcatheter arterial chemoembolization(TACE)-based therapy for unresectable hepatocellular carcinoma(uHCC)remains limited.This study aimed to investigate the efficacy and safet...
Congenital heart disease(CHD)affects about 1%of live births.Among them,about 20%will undergo one or more surgical or percutaneous maneuvers on the right ventricle outflow tract or pulmonary valve.Transcatheter pulmona...
supported by the National Key R&D Program of China(2022YFC2503400);Major science and technology special plan project of Yunnan Province(202302AA310045);Yunnan Provincial Clinical Research Center for Cardiovascular Diseases(202102AA310002).
Transcatheter edge-to-edge repair(TEER)of the mitral valve has emerged as a standard treatment for patients with severe degenerative mitral regurgitation at high or prohibitive surgical risk.The devices approved by th...
supported by the National Key Project of Research and Development Plan during the fourteenth Five-year Plan Period(2022YFC2503400).
Objectives:The aim of this multicenter,prospective,single-arm pilot study(ClinicalTrials.gov number:NCT05040074)was to observe the procedural and 30-day results of the novel transcatheter mitral valve repair system,SQ...
This study is part of the China Degenerative Valve Disease II Cohort Study(China-DVD2 Study,NCT05044338);which is supported by the National Key R&D Program of China(2020YFC200801100).
Objective:To evaluate the feasibility,safety,and effectiveness of a novel edge-to-edge mitral valve repair system(the NovoClasp system)in patients with severe mitral regurgitation.Methods:In this prospective,single-ar...
National Key Researchand Development Program(2022YFC2503400);Yunnan Provincial Clinical Research Center for Cardiovascular Diseases(202302AA310045).
objective:Severe tricuspid regurgitation frequently leads to increased mortality and a poor prognosis.Transcatheter edge-to-edge repair(TEER)for tricuspid valve regurgitation has been reported as a safe alternative to...